Completed PHASE1 INTERVENTIONAL 2-arm NCT05186129

Bioequivalence Study of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® 75 mg Tablet After Oral Administration to Healthy Adult Subjects Under Fasting Condition

To Determine the Bioequivalence of Clopid® (Clopidogrel) 75 mg Tablet Manufactured by Ferozsons Laboratories Ltd. Pakistan and Plavix® 75 mg Tablet Manufactured by Sanofi Winthrop Industrie France for Sanofi Pakistan After Oral Administration to Healthy Adult Male Subjects Under Fasting Condition

Sponsor: Center for Bioequivalence Studies and Clinical Research

Conditions Bioequivalence

Interventions Clopid® 75 mg Tablet Plavix® 75mg Tablet

Updated 4 times since 2022 Last updated: Feb 14, 2022 Started: Apr 6, 2018 Primary completion: Apr 15, 2018 Completion: Apr 20, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05186129, this PHASE1 trial focuses on Bioequivalence and remains completed. Sponsored by Center for Bioequivalence Studies and Clinical Research, it has been updated 4 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2022 — Jul 2024 [monthly]

Completed PHASE1
Feb 2022 — Apr 2022 [monthly]

Completed PHASE1

First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Center for Bioequivalence Studies and Clinical Research
Ferozsons Laboratories Ltd.

Data source: Center for Bioequivalence Studies and Clinical Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Karachi, Pakistan